Shimadzu and bioMerieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMerieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF mass spectrometry technology for optimized integration into the microbiology laboratory workflow.

KYOTO, Japan and MARCY L'ETOILE, France , May 21 /- Shimadzu and bioMerieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMerieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt ...

bioMerieux and Knome announced today that they have entered into a strategic agreement to collaborate in the development of next-generation, sequence-based in vitro diagnostics. Under the agreement, bioMerieux will have exclusive rights to license Knome's proprietary genome analysis platform for use in the in vitro diagnostics market.

bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) ...

DURHAM, N.C. , March 11 /- bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). ...

ExonHit Therapeutics and bioMérieux have decided not to pursue their collaboration in colon cancer, following a recent review of data by their scientific committee. Both companies continue to collaborate in the field of prostate cancer.

ASHBURN, Va., Dec. 28 /- Brainware, Inc., an innovative provider of intelligent data capture and enterprise search solutions , today announced that bioMerieux, a global biotechnology company headquartered in Lyon France, has selected the company's Brainware Distiller(TM) solution to automate its accounts payable process. bioMerieux maintains a ...

MARCY L'ETOILE, France, Nov. 17 /- bioMerieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast ...

DURHAM, N.C., Oct. 28 /- bioMerieux - a world leader in the field of in vitro diagnostics - today announced the U.S. launch of chromID MRSA, a simple and cost-effective solution in the struggle against MRSA. The product recently received FDA 510(k) clearance for the detection of MRSA, ...